

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail

[Translation]

September 1, 2022

To: Shareholders

Company Name: Renascience Inc

Name of Representative: Koji Naito, President & CEO

(Code: 4889 TSE Growth)

Inquiries: Hiroyasu Ishimaru, Corporate Officer in Charge of
Administration and Corporate Planning

**Announcement of the Execution of the Collaboration Agreement with
HI-LEX Corporation and its subsidiary HI-LEX Medical**

The Company is pleased to announce the execution of a collaboration agreement (“Agreement”) with HI-LEX Corporation (“HI-LEX”) and its subsidiary HI-LEX Medical (“HL Medical”) on the development of medical devices including artificial intelligence (“AI”).

1. Background of the Agreement.

The Company conducts research and development of various modalities (pharmaceuticals, medical devices, and other treatments) to solve medical issues and is engaged in the development of medical solutions using medical devices and AI. The Company is currently working with HL Medical on the development of a guide catheter used in a disposable ultrafine endoscope for peritoneal dialysis. The Company executed the Agreement to jointly promote the development of medical devices that utilize AI and other products with HI-LEX and HL Medical.

2. Details of the Agreement

The Company will promote the collaborative research and development of multiple medical devices including AI that will be useful for diagnosis and therapy in the medical field, at the Tohoku University Renascience Open Innovation Labo (TREx), a research center established in Tohoku University Graduate School of Medicine in December 2021, by utilizing the manufacturing technologies of HI-LEX and Hi Medical for medical devices and the medical information owned by HI-LEX and HL Medical. The resulting AI solutions will be promptly evaluated in clinical trials at universities and other medical institutions, leading to their practical application.

3. Outlook for the future

This matter will have no impact on the earnings forecast for the fiscal year ending March 31, 2023.

< Reference >

[HI-LEX Corporation]

Since its establishment in 1946, HI-LEX Corporation has focused on the usefulness of control cable technology and has grown along with the development of the automotive industry. Currently, HI-LEX Corporation supplies control cables to all automobile manufacturers in Japan and hold the number one position with an overwhelming share of the market. Overseas, HI-LEX Corporation also supplies products to the Big Three automakers and other major automakers and has formed a corporate group with consolidated annual sales exceeding 230 billion yen. Based on the extrusion technology of resin tubes, one of the ultra-precision molding processing technologies, that HI-LEX Corporation has cultivated for many years in the control cable business, HI-LEX Corporation has further developed the technology to process the materials with fine diameter and minute sizes, and are now capable of producing resin, metal, and composite products for medical applications. HI-LEX Corporation has received ISO13485 certification, the international standard for quality management systems in medical devices, on October 13, 2005.

For more information, please visit the website at <https://secure.hi-lex.co.jp/> and for more information on the medical device division, please visit the website at <https://secure.hi-lex.co.jp/medical/>.

[HI-LEX Medical]

HI-LEX Medical was established in 2021 as a wholly owned subsidiary of HI-LEX Corporation for the purpose of importing and selling medical devices. HI-LEX Medical's business includes import and sales of medical devices and pharmaceuticals, repair and maintenance of medical devices, support services related to medical care (research and provision of various information, management, logistics, establishment of facilities, etc.), and support services for medical device development (discovery of seeds and provision of needs). For more information, please visit the website at <https://www.hi-lexmedical.com/>.

End